Tumor suppression function of FoxD3 in lung cancer

Irish Journal of Medical Science

Volumn 185, Issue 3, 2016, Pages 547-553

  Wang, C ^a   Huang, Y ^b   Dai, W ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; FoxD3; Lung cancer; Proliferation

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; FORKHEAD TRANSCRIPTION FACTOR; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FORKHEAD BOX D3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; FOXD3 PROTEIN, HUMAN;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG CANCER CELL LINE; PC9 CELL LINE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; A-549 CELL LINE; ADENOCARCINOMA; ANIMAL; GENETICS; IMMUNOLOGY; LUNG TUMOR; TUMOR SUPPRESSOR GENE;

A549 CELLS; ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS;

EID: 84928137521     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-015-1297-2     Document Type: Article

References (34)

1. Cooper WA et al (2013) Molecular biology of lung cancer. J Thorac Dis 5(Suppl 5):S479–S490
2. Weigel D, Jackle H (1990) The fork head domain: a novel DNA binding motif of eukaryotic transcription factors? Cell 63(3):455–456
3. Sutton J et al (1996) Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells. J Biol Chem 271(38):23126–23133
4. Hanna LA et al (2002) Requirement for Foxd3 in maintaining pluripotent cells of the early mouse embryo. Genes Dev 16(20):2650–2661
5. Tompers DM et al (2005) Foxd3 is required in the trophoblast progenitor cell lineage of the mouse embryo. Dev Biol 285(1):126–137
6. Arduini BL (2012) Brivanlou AH Modulation of FoxD3 activity in human embryonic stem cells directs pluripotency and paraxial mesoderm fates. Stem Cells 30(10):2188–98
7. Liu Y, Labosky PA (2008) Regulation of embryonic stem cell self-renewal and pluripotency by Foxd3. Stem Cells 26(10):2475–2484
8. Pan G et al (2006) A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. Faseb J 20(10):1730–1732
9. Plank JL et al (2014) Transcriptional targets of Foxd3 in murine ES cells. Stem Cell Res 12(1):233–40
10. Guo Y et al (2002) The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci USA 99(6):3663–3667
11. Kos R et al (2001) The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos. Development 128(8):1467–1479
12. Barembaum M, Bronner-Fraser M (2005) Early steps in neural crest specification. Semin Cell Dev Biol 16(6):642–646
13. Katiyar P, Aplin AE (2011) FoxD3 regulates migration properties and Rnd3 expression in melanoma cells. Mol Cancer Res 9(5):545–52
14. Hromas R et al (1999) Genesis, a Winged Helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model. Cell Tissue Res 297(3):371–382
15. Dottori M et al (2001) The winged-helix transcription factor Foxd3 suppresses interneuron differentiation and promotes neural crest cell fate. Development 128(21):4127–4138
16. Nitzan E et al (2013) Neural crest and Schwann cell progenitor-derived melanocytes are two spatially segregated populations similarly regulated by Foxd3. Proc Natl Acad Sci USA 110(31):12709–14
17. Fairchild CL et al (2014) FoxD3 regulates cranial neural crest EMT via downregulation of tetraspanin18 independent of its functions during neural crest formation. Mech Dev 132:1–12
18. Thomas AJ, Erickson CA (2009) FoxD3 regulates the lineage switch between neural crest-derived glial cells and pigment cells by repressing MITF through a non-canonical mechanism. Development 136(11):1849–1858
19. Abel EV, Aplin AE (2010) FoxD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Res 70(7):2891–900
20. Cheng AS et al (2013) Helicobacter pylori causes epigenetic dysregulation of FoxD3 to promote gastric carcinogenesis. Gastroenterology 144(1):122–133 e9
21. Liu LL et al (2014) FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget 5(13):5113–24
22. Zhao H et al (2014) Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast. Int J Clin Exp Pathol 7(2):670–676
23. Chu TL et al (2014) FoxD3 deficiency promotes breast cancer progression by induction of epithelial-mesenchymal transition. Biochem Biophys Res Commun 446(2):580–584
24. Li D et al (2013) FoxD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget 4(11):2021–2044
25. Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954
26. Papin C et al (1998) Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J Biol Chem 273(38):24939–24947
27. Hoeflich KP et al (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66(2):999–1006
28. Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65(10):3980–3985
29. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195(2):127–137
30. Fidler MJ et al (2012) Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol 4(2):51–60
31. Cappuzzo F et al (2006) Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17(7):1120–1127
32. Cappuzzo F et al (2009) Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 21(3):562–567
33. Ludovini V et al (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20(5):842–849
34. Nakagawa M et al (2012) Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer 13(2):136–142